← Lung Cancer

The Implications of 9th Lung Cancer TNM Classification on Interventional Pulmonology

IPBronch Review

Clinical context

The 9th edition of the TNM classification, effective January 2025, introduces granular changes to N and M descriptors that directly impact staging and therapeutic decision-making. For the Interventional Pulmonologist, the subdivision of N2 into N2a (single station) and N2b (multiple stations) necessitates a shift toward more precise, systematic mediastinal sampling to avoid under-staging, which now carries significant prognostic and treatment-allocation implications.

Strengths and weaknesses

Takeaway

1. Precision Matters: With the N2a/N2b split, your staging report must explicitly document the specific nodal stations sampled. 2. Contamination Risk: Be aware that the majority of practitioners do not change needles between N2 stations, yet the clinical impact of potential cross-contamination remains an open question—await results from NCT07418450. 3. Technological Evolution: While conventional EBUS remains the gold standard, thin convex-probe EBUS and robotic-assisted platforms are expanding our reach into subsegmental (N1) and peripheral (stations 5/6) nodes, which may soon become part of routine staging. 4. Molecular Yield: Prioritize cryo-EBUS or high-quality core acquisition when molecular profiling is the primary goal, especially in never-smokers.


Respirology, EarlyView.
Read the full paper ↗

Keep reading

N opens the next one